Cell and biomaterial delivery strategies to induce immune tolerance

Adv Drug Deliv Rev. 2023 Dec:203:115141. doi: 10.1016/j.addr.2023.115141. Epub 2023 Nov 18.

Abstract

The prevalence of immune-mediated disorders, including autoimmune conditions and allergies, is steadily increasing. However, current therapeutic approaches are often non-specific and do not address the underlying pathogenic condition, often resulting in impaired immunity and a state of generalized immunosuppression. The emergence of technologies capable of selectively inhibiting aberrant immune activation in a targeted, antigen (Ag)-specific manner by exploiting the body's intrinsic tolerance pathways, all without inducing adverse side effects, holds significant promise to enhance patient outcomes. In this review, we will describe the body's natural mechanisms of central and peripheral tolerance as well as innovative delivery strategies using cells and biomaterials targeting innate and adaptive immune cells to promote Ag-specific immune tolerance. Additionally, we will discuss the challenges and future opportunities that warrant consideration as we navigate the path toward clinical implementation of tolerogenic strategies to treat immune-mediated diseases.

Keywords: Adaptive immune responses; Adoptive cell therapies; Antigen delivery systems; Autoimmune diseases; Immune tolerance; Innate immune response; Nanoparticles.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antigens
  • Biocompatible Materials*
  • Humans
  • Hypersensitivity*
  • Immune Tolerance
  • Immunosuppression Therapy / methods

Substances

  • Biocompatible Materials
  • Antigens